V1RC16 Inhibitors
V1RC16 inhibitors encompass a range of compounds that attenuate the signaling pathways and biological processes, which could logically lead to the inhibition of V1RC16 activity. For example, compounds targeting kinases such as erlotinib and gefitinib, which are EGFR inhibitors, could indirectly diminish V1RC16's activity by inhibiting the EGFR signaling cascade that might activate V1RC16. Similarly, rapamycin, functioning as an mTOR inhibitor, and LY294002, a PI3K inhibitor, could suppress V1RC16's role if it is downstream of the mTOR or PI3K/AKT pathways, respectively. The inhibition of these pathways, essential for various cellular functions such as growth and proliferation, could therefore impede any V1RC16-related processes that are reliant on these upstream signals. Additionally, the cell cycle is a critical aspect of cellular regulation, and inhibitors such as palbociclib and PD0332991, which target CDK4/6, could indirectly restrain V1RC16 activity by stalling cell cycle progression, assuming V1RC16 is involved in cell cycle regulation.
Trametinib and SP600125, which inhibit the MAPK/ERK and JNK pathways respectively, and ZM336372, a RAF kinase inhibitor, could each contribute to the functional inhibition of V1RC16 by altering signaling events within these critical pathways, should V1RC16 be a participant in or regulated by these routes. Furthermore, WZ4003 and Dorsomorphin target NUAK1 and BMP/AMPK signaling pathways, proposing that if V1RC16's function is mediated through these pathways, their inhibition would logically lead to a reduction in V1RC16 activity. Collectively, these inhibitors act on a diverse array of cellular processes, but all converge on the common outcome of potentially decreasing the functional activity of V1RC16 by targeting specific signaling pathways and biological processes implicated in its activation and regulation.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is a tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR). Since V1RC16 might be activated by EGFR signaling, erlotinib can indirectly inhibit V1RC16 by blocking this upstream pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor affecting the mammalian target of rapamycin (mTOR) pathway. Since V1RC16 could be downstream of mTOR signaling, rapamycin may lead to the functional inhibition of V1RC16 by suppressing the pathway it is involved in. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor that impedes the cell cycle progression. If V1RC16 is associated with the cell cycle regulation, inhibition of CDK4/6 could indirectly decrease V1RC16 activity by halting the cell cycle. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several receptor tyrosine kinases, potentially including those that activate V1RC16. By inhibiting these kinases, sorafenib can decrease the functional activity of V1RC16. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that impedes the MAPK/ERK pathway. If V1RC16's function is regulated by this pathway, trametinib could lead to the functional inhibition of V1RC16 by blocking MAPK signaling. | ||||||
WZ4003 | 1214265-58-3 | sc-473979 | 5 mg | $300.00 | ||
WZ4003 is a selective NUAK1 inhibitor. If V1RC16 is regulated by NUAK1-dependent signaling pathways, then inhibiting NUAK1 with WZ4003 would indirectly decrease V1RC16 activity. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
ZM336372 is a potent RAF kinase inhibitor, which could affect the RAF/MEK/ERK pathway. By targeting this pathway, ZM336372 might indirectly inhibit V1RC16 if it is associated with this signaling cascade. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that hampers the PI3K/AKT signaling pathway. If V1RC16 is part of or regulated by this pathway, LY294002 would lead to its functional inhibition by interfering with PI3K/AKT signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK pathway. Inhibition of JNK could lead to a reduction in V1RC16 activity if V1RC16 is regulated by JNK signaling. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $96.00 $355.00 | 69 | |
Dorsomorphin is an inhibitor of BMP signaling and AMPK. By targeting these pathways, it might indirectly inhibit V1RC16 if V1RC16's activity is modulated by BMP or AMPK signaling. | ||||||